We designed a novel treatment strategy by combining DTX with a potent and selective CXCR2 antagonist SB225002 in these orthotopic breast tumor mouse models46,47 (Supplementary Fig. S23a, b) and found that the combination of DTX and SB225002 showed a more significant inhibiting effect on tumor growth than either treatment alone in both syngeneic mice and humanized mice bearing CCL20high-expressing breast cancer cell allograft or xenograft tumors (Fig. 6a–d and Supplementary Figs. S23c, S24a–c). The gene discussed is CXCR2; the disease is neoplasm.